Drug Profile
Research programme: cardio and neuroprotective cyclophilin inhibitors - Abliva/Isomerase Therapeutics
Alternative Names: NCCIM; Non-Ciclosporin Cyclophilin Inhibiting Molecules; NVP 019; Sangamides - AblivaLatest Information Update: 05 Jun 2020
Price :
$50
*
At a glance
- Originator Biotica Technology
- Developer Abliva; Isomerase Therapeutics
- Class Macrolides; Neuroprotectants
- Mechanism of Action Cyclophilin D inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries; Cardiovascular disorders
Most Recent Events
- 28 May 2020 NeuroVive Pharmaceutical is now called Abliva
- 28 Jul 2018 No recent reports of development identified for preclinical development in Brain injuries(Prevention) in Sweden (IV)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders(Prevention of relapse) in Sweden (IV)